Back to Search
Start Over
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression.
- Source :
-
Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2018 Aug; Vol. 38 (8), pp. 1459-1467. Date of Electronic Publication: 2018 Mar 12. - Publication Year :
- 2018
-
Abstract
- Background and Aim: In patients with HCV-related cirrhosis, a sustained virological response may lead to cirrhosis regression. Whether histological changes translate into prevention of long-term complications, particularly hepatocellular carcinoma is still unknown. This was investigated in a cohort of histological cirrhotics who had been prospectively followed-up for 10 years after the achievement of a sustained virological response to IFN.<br />Methods: In all, 38 sustained virological response cirrhotics who underwent a liver biopsy 5 years post-SVR were prospectively followed to assess the impact of cirrhosis regression on clinical endpoints.<br />Results: During a follow-up of 86 (30-96) months from liver biopsy, no patients developed clinical decompensation, whilst 5 (13%) developed hepatocellular carcinoma after 79 (7-88) months. The 8-year cumulative probability of hepatocellular carcinoma was 17%, without differences between patients with or without cirrhosis regression (19% [95% CI 6%-50%] vs 14% [95% CI 4%-44%], P = .88). Patients who developed or did not an hepatocellular carcinoma had similar rates of residual cirrhosis (P = 1.0), collagen content (P = .48), METAVIR activity (P = .34), portal inflammation (P = .06) and steatosis (P = .17). At baseline, patients who developed an hepatocellular carcinoma had higher γGT (HR 1.03, 95% CI 1.00-1.06; P = .014) and glucose (HR 1.02, 95% CI 1.00-1.02; P = .012) values; moreover, they had increased Forns Score (HR 12.8, 95% CI 1.14-143.9; P = .039), Lok Index (HR 6.24, 95% CI 1.03-37.6; P = .046) and PLF (HR 19.3, 95% CI 1.72-217.6; P = .016) values. One regressor died of lung cancer. The 8-year cumulative survival probability was 97%, independently on cirrhosis regression (96% vs 100%, P = 1.0) or hepatocellular carcinoma (100% vs 97%, P = 1.0).<br />Conclusions: Post-SVR cirrhosis regression does not prevent hepatocellular carcinoma occurrence.<br /> (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Subjects :
- Aged
Antiviral Agents therapeutic use
Carcinoma, Hepatocellular mortality
Female
Fibrosis
Humans
Interferons therapeutic use
Italy
Liver Cirrhosis pathology
Liver Neoplasms mortality
Liver Neoplasms pathology
Male
Middle Aged
Proportional Hazards Models
Prospective Studies
Regression Analysis
Risk Factors
Sustained Virologic Response
Carcinoma, Hepatocellular complications
Hepatitis C complications
Hepatitis C drug therapy
Liver Cirrhosis complications
Liver Neoplasms complications
Subjects
Details
- Language :
- English
- ISSN :
- 1478-3231
- Volume :
- 38
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Liver international : official journal of the International Association for the Study of the Liver
- Publication Type :
- Academic Journal
- Accession number :
- 29377616
- Full Text :
- https://doi.org/10.1111/liv.13707